Raltegravir and Elvitegravir are the medications that act by binding with integrase enzyme. They prevent human immunodeficiency virus (HIV) from incorporating its genetic material into the client's cell. They belong to the group of drugs called integrase inhibitors, because they lock the action of the viral enzyme that inserts the viral genome into the DNA of the host cell.
